ABSTRACT
Background/Objectives Serum proteomic analysis of deeply-phenotyped samples, biological pathway modeling and network analysis were performed to elucidate the inflammatory and neurodegenerative processes of multiple sclerosis (MS) and identify sensitive biomarkers of MS disease activity (DA).
Methods Over 1100 serum proteins were evaluated in >600 samples from three MS cohorts to identify biomarkers of clinical and radiographic (gadolinium-enhancing lesions) new MS DA. Protein levels were analyzed and associated with presence of gadolinium-enhancing lesions, clinical relapse status (CRS), and annualized relapse rate (ARR) to create a custom assay panel.
Results Twenty proteins were associated with increased clinical and radiographic MS DA. Serum neurofilament light chain (NfL) showed the strongest univariate correlation with radiographic and clinical DA measures. Multivariate modeling significantly outperformed univariate NfL to predict gadolinium lesion activity, CRS and ARR.
Discussion These findings provide insight regarding correlations between inflammatory and neurodegenerative biomarkers and clinical and radiographic MS DA.
Funding Octave Bioscience, Inc (Menlo Park, CA).
Competing Interest Statement
T.C. has received compensation for consulting from Biogen, Novartis Pharmaceuticals, Roche Genentech, and Sanofi Genzyme, and received research support from the National Institutes of Health, National MS Society, US Department of Defense, EMD Serono, I-Mab Biopharma, Novartis Pharmaceuticals, Octave Bioscience, Inc, Roche Genentech, and Tiziana Life Sciences. V.M.G., M.B, and A.K. were employees of Octave Bioscience, Inc at the time the study was completed. R.B. is funded by the NMSS Harry Weaver Award, NIH, DOD, NSF, as well as Biogen, Novartis and Roche Genentech. She has received personal fees for consulting from Alexion, EMD Serono, Horizon, Jansen, Genzyme Sanofi, and TG Therapeutics. B.C. has received personal compensation for consulting from Alexion, Atara, Autobahn, Avotres, Biogen, Boston Pharma, EMD Serono, Gossamer Bio, Hexal/Sandoz, Horizon, Immunic AG, Neuron23, Novartis, Sanofi, Siemens and TG Therapeutics and received research support from Genentech. S.L. H. currently serves on the scientific advisory board of Accure, Alector, and Annexon; board of directors of Neurona; and has previously consulted for BD, Moderna, and NGM Bio. Dr. Hauser also has received travel reimbursement and writing support from F. Hoffmann-La Roche and Novartis AG for anti-CD20-therapy-related meetings and presentations and is supported by grants from the NIH/NINDS (R35NS111644). R.G. H. has received fees for consultation from Roche/Genentech, Novartis, Neuron23, QIA Consulting, and research funding from Roche/Genentech and Atara. H.L. has received research support from the US Department of Defense and Octave Bioscience, Inc. A.P. is currently an employee of Moderna Therapeutics. H.Y., R.G., S.S., S.C., and AS have nothing to disclose. F.Q. is an employee of Octave Bioscience, Inc. N.S. has received Sylvia Lawry Physician Fellowship Award from the National MS Society. She has also received compensation for consulting from EMD Serono. H.W. has received research support from the Department of Defense, Genentech, Inc., National Institutes of Health, National Multiple Sclerosis Society, Novartis, and Sanofi Genzyme. He has received compensation for consulting from Genentech, Inc., IM Therapeutics, IMAB Biopharma, MedDay Pharmaceuticals, Tiziana Life Sciences, and vTv Therapeutics. S.B. is co-Founder of Mate Bioservices
Funding Statement
The study was supported by funding from Octave Bioscience, Inc (Menlo Park, CA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol and study procedures were approved by institutional review boards and independent ethics committees at each study site. The University of California San Francisco Institutional Review Board granted ethical approval for the EPIC Cohort. Massachusetts General Brigham Human Research Committee granted ethical approval for the CLIMB Cohort. Western Institutional Review Board, Copernicus Group IRB, Sheperd Center Research Review Committee, Institutional Review Board for Human Research at St. Joseph's Hospital and Medical Center, University of Massachusetts Medical School Committee for the Protection of Human Subjects in Research, Ohio State University Biomedical Institutional Review Board, Beth Israel Deaconess Medical Center Committee on Clinical Investigations, John Hopkins medicine Office of Human Subjects Research Institutional Review Board, and the Southwestern Medical Center Institutional Review Board all granted ethical approval for the ACP Cohort.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Access to data can be provided after a research proposal is submitted to the corresponding author and a data sharing agreement is in place.
